DSM-Firmenich Reiterates 2026 Adjusted EBITDA Margin Outlook
The company reiterated its outlook for an adjusted EBITDA margin of around 20% in 2026.
Related stories
Marksans Pharma September-Quarter Revenue From Operations at 9.40 Billion Rupees
M impact | EARNINGS | Nov 04, 2026, 07:58 AM UTC
Marksans Pharma Reports September-Quarter Consolidated Net Profit of 1.41 Billion Rupees
M impact | EARNINGS | Nov 04, 2026, 07:58 AM UTC
Pandora Raises 2026 Targets on Demand for New Products
Pandora raised its 2026 targets, supported by demand for new products.
M impact | EARNINGS | Nov 04, 2026, 07:58 AM UTC
Magle Chemoswed Reports Q3 Sales of SEK 70.9 Million
M impact | EARNINGS | Nov 04, 2026, 07:56 AM UTC
Magle Chemoswed Q3 EBITDA SEK -31.1 million
M impact | EARNINGS | Nov 04, 2026, 07:56 AM UTC
Magle Chemoswed Reports Q3 Net Income of SEK -107.1 Million
M impact | EARNINGS | Nov 04, 2026, 07:56 AM UTC